WHO WE ARE
Founded in 2018, we are an international leader in the development of in-vivo biomarkers to guide targeted therapies in oncology.
We develop in-vivo biomarkers transforming oncology, guiding treatment selection and monitoring, improving patients’ pathway and quality of life. Within a Positron Emission Tomography exam (PET Scan), biomarkers help oncologists and nuclear medicine physicians personalize the treatment, based on whole body imaging providing the localization and characteristics of tumors.
MEET OUR TEAM
Meet our team of experts in in-vivo biomarkers for oncology with strong competencies in executive leadership, R&D, industry regulations and operations: